Nathaniel Hearn Jr.

A Cooley team advised Horizon Therapeutics, a specialty biopharmaceutical company, on its agreement to be acquired by Amgen. The approximately $28 billion merger would represent the third-largest all-cash transaction in the pharmaceutical sector in history and the biggest healthcare deal of 2022.

Cooley advised Movable Ink, an artificial intelligence-powered personalized content platform, on its definitive agreement to be acquired by STG. The transaction is expected to close in July 2025.

Cooley advised Medically Home, a provider of a hospital-at-home technology enablement model for health systems and physician groups to safely deliver emergency and hospital-level care at home, on its merger with DispatchHealth, a provider of high-acuity, in-home medical care for people experiencing serious health concerns. 

Cooley advised Datadog (Nasdaq: DDOG), a monitoring and security platform for cloud applications, on its acquisition of Eppo, a feature flagging and experimentation platform that will tightly integrate with Datadog’s existing product analytics suite.

Cooley advised Chimerix (Nasdaq: CMRX), a biopharmaceutical company with a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, on its definitive agreement to be acquired by Jazz Pharmaceuticals (Nasdaq: JAZZ) for $8.55 per share in cash – totaling approximately $935 million.